Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID)-Reference-Cited by-同舟云学术

Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID)

Published:2015-09-10 Issue:3 Volume:17 Page:206-215
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Rougemont M¹,Nchotu Ngang P²,Stoll B³,Delhumeau C¹,Hill A⁴,Ciaffi L¹,Bonnet F⁵,Menga G²,Fampou J-C²,Calmy A¹

Affiliation:

1. HIV Unit; Division of Infectious Diseases; Department of Internal Medical Specialties; Geneva University Hospitals; Geneva Switzerland

2. National Social Insurance Hospital; Approved Treatment Center; Yaounde Cameroon

3. Institute of Global Health; Faculty of Medicine; University of Geneva; Geneva Switzerland

4. Pharmacology Research Laboratories; University of Liverpool; Liverpool UK

5. CHU de Bordeaux; Service de Médecine Interne et Maladies Infectieuses & INSERM U897; Université de Bordeaux; Bordeaux France

Funder

ViiV Healthcare

Gilead Sciences

AbbVie

Meso Scale Diagnostics

Bill and Melinda Gates Foundation

‘Projet de Recherche et Développement’ of the University of Geneva Hospitals

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference25 articles.

1. Dose optimisation: a strategy to improve tolerability and lower antiretroviral drug prices in low and middle income countries;Hill;Open Infect Dis J,2010

2. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial;ENCORE1 Study Group;Lancet,2014

3. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement;Crawford;Lancet Infect Dis,2012

4. Hicks C Haas D Seekins D et al A Phase II, double blind, placebo controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (DMP-266) in combination with open-label AZT with lamivudine at 24 weeks (DMP 266-005) 5th Conference on Retroviruses and Opportunistic Infections 1998

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study;JMIR Public Health and Surveillance;2022-06-24

2. Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study (Preprint);2021-09-07

3. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa;Journal of Antimicrobial Chemotherapy;2017-02-04